NATCOPHARMPharmaceuticals
Natco Pharma Ltd — Profit & Loss Statement
₹974.20
+0.51%
Natco Pharma Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.00 | -0.09 Cr | 3.82 Cr | — |
| Tax Rate For Calcs | 0.18 | 0.17 | 0.17 | 0.16 | — |
| Normalized EBITDA | 2.55K Cr | 1.88K Cr | 1.04K Cr | 334.00 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 1.89K Cr | 1.39K Cr | 715.30 Cr | 170.00 Cr | — |
| Reconciled Depreciation | 235.20 Cr | 186.80 Cr | 163.80 Cr | 142.60 Cr | — |
| Reconciled Cost Of Revenue | 689.80 Cr | 716.60 Cr | 745.50 Cr | 681.50 Cr | — |
| EBITDA | 2.55K Cr | 1.88K Cr | 1.04K Cr | 358.00 Cr | — |
| EBIT | 2.32K Cr | 1.69K Cr | 871.40 Cr | 215.40 Cr | — |
| Net Interest Income | -23.90 Cr | -19.20 Cr | 36.70 Cr | 21.30 Cr | — |
| Interest Expense | 23.90 Cr | 19.20 Cr | 9.50 Cr | 13.20 Cr | — |
| Normalized Income | 1.89K Cr | 1.39K Cr | 715.71 Cr | 149.82 Cr | — |
| Net Income From Continuing And Discontinued Operation | 1.89K Cr | 1.39K Cr | 715.30 Cr | 170.00 Cr | — |
| Total Expenses | 2.47K Cr | 2.43K Cr | 1.91K Cr | 1.76K Cr | — |
| Diluted Average Shares | 17.91 Cr | 17.95 Cr | 18.26 Cr | 18.24 Cr | — |
| Basic Average Shares | 17.91 Cr | 17.95 Cr | 18.26 Cr | 18.24 Cr | — |
| Diluted EPS | 105.26 | 77.34 | 39.18 | 9.32 | — |
| Basic EPS | 105.26 | 77.34 | 39.18 | 9.32 | — |
| Diluted NI Availto Com Stockholders | 1.89K Cr | 1.39K Cr | 715.30 Cr | 170.00 Cr | — |
| Net Income Common Stockholders | 1.89K Cr | 1.39K Cr | 715.30 Cr | 170.00 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 1.89K Cr | 1.39K Cr | 715.30 Cr | 170.00 Cr | — |
| Minority Interests | 2.00 Cr | 0.00 | 0.00 | 0.00 | — |
| Net Income Including Noncontrolling Interests | 1.88K Cr | 1.39K Cr | 715.30 Cr | 170.00 Cr | — |
| Net Income Continuous Operations | 1.88K Cr | 1.39K Cr | 715.30 Cr | 170.00 Cr | — |
| Tax Provision | 408.00 Cr | 285.20 Cr | 146.60 Cr | 32.20 Cr | — |
| Pretax Income | 2.29K Cr | 1.67K Cr | 861.90 Cr | 202.20 Cr | — |
| Other Non Operating Income Expenses | 354.50 Cr | 128.10 Cr | 14.10 Cr | 5.60 Cr | — |
| Net Non Operating Interest Income Expense | -23.90 Cr | -19.20 Cr | 36.70 Cr | 21.30 Cr | — |
| Interest Expense Non Operating | 23.90 Cr | 19.20 Cr | 9.50 Cr | 13.20 Cr | — |
| Operating Income | 1.96K Cr | 1.56K Cr | 790.10 Cr | 140.80 Cr | — |
| Operating Expense | 1.78K Cr | 1.72K Cr | 1.16K Cr | 1.08K Cr | — |
| Other Operating Expenses | 949.20 Cr | 1.01K Cr | 222.60 Cr | 229.20 Cr | — |
| Depreciation And Amortization In Income Statement | 235.20 Cr | 186.80 Cr | 163.80 Cr | 142.60 Cr | — |
| Depreciation Income Statement | 235.20 Cr | 186.80 Cr | 163.80 Cr | 142.60 Cr | — |
| Gross Profit | 3.74K Cr | 3.28K Cr | 1.95K Cr | 1.22K Cr | — |
| Cost Of Revenue | 689.80 Cr | 716.60 Cr | 745.50 Cr | 681.50 Cr | — |
| Total Revenue | 4.43K Cr | 4.00K Cr | 2.70K Cr | 1.90K Cr | — |
| Operating Revenue | 4.43K Cr | 4.00K Cr | 2.70K Cr | 1.90K Cr | — |
| Total Unusual Items | — | -7.50 Cr | -0.50 Cr | 24.00 Cr | 20.30 Cr |
| Total Unusual Items Excluding Goodwill | — | -7.50 Cr | -0.50 Cr | 24.00 Cr | 20.30 Cr |
| Interest Income | — | 101.00 Cr | 51.20 Cr | 39.00 Cr | 56.60 Cr |
| Rent Expense Supplemental | — | 5.90 Cr | 4.90 Cr | 3.20 Cr | 3.00 Cr |
| Special Income Charges | — | -6.80 Cr | 4.70 Cr | 22.80 Cr | 20.30 Cr |
| Other Special Charges | — | 1.70 Cr | -17.80 Cr | -42.70 Cr | -32.00 Cr |
| Write Off | — | 5.10 Cr | 13.10 Cr | 19.90 Cr | 11.70 Cr |
| Total Other Finance Cost | — | 7.20 Cr | 5.00 Cr | 4.50 Cr | 4.50 Cr |
| Interest Income Non Operating | — | 101.00 Cr | 51.20 Cr | 39.00 Cr | 56.60 Cr |
| Research And Development | — | 141.70 Cr | 90.20 Cr | 176.90 Cr | 147.30 Cr |
| Selling General And Administration | — | 268.30 Cr | 203.00 Cr | 125.50 Cr | 90.60 Cr |
| Selling And Marketing Expense | — | 153.00 Cr | 96.10 Cr | 43.70 Cr | 34.10 Cr |
| General And Administrative Expense | — | 115.30 Cr | 106.90 Cr | 81.80 Cr | 56.50 Cr |
| Rent And Landing Fees | — | 5.90 Cr | 4.90 Cr | 3.20 Cr | 3.00 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Natco Pharma Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.